Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, phase II, open label study of postoperative concurrent
chemoradiotherapy with docetaxel for high-risk squamous cell carcinoma of the head and
neck(HNSCC).The primary purpose of this study is to evaluate the efficacy and safety of
concurrent chemoradiotherapy with docetaxel in HNSCC patients.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University